ArticleJournal of molecular neuroscience : MN2004
SRC-1 is involved in the control of the gene expression of myelin protein Po.
Article in Journal of molecular neuroscience : MN, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 19 citations in OpenAlex.
- Steroid receptor coactivator-1: The central intermediator linking multiple signals and functions in the brain and spinal cord.Genes & diseases · 2022Review
- Physiopathological Role of Neuroactive Steroids in the Peripheral Nervous System.International journal of molecular sciences · 2020Review
- Genomic and Non-genomic Action of Neurosteroids in the Peripheral Nervous System.Frontiers in neuroscience · 2020Review
- Review
- Role of neuroactive steroids in the peripheral nervous system.Frontiers in endocrinology · 2011Article
- Modulation of steroid action in the central and peripheral nervous systems by nuclear receptor coactivators.Psychoneuroendocrinology · 2009Review
- Progesterone derivatives increase expression of Krox-20 and Sox-10 in rat Schwann cells.Journal of molecular neuroscience : MN · 2007Article
- Neuroactive steroids: A therapeutic approach to maintain peripheral nerve integrity during neurodegenerative events.Journal of molecular neuroscience : MN · 2006Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Steroid receptor coactivator-1 (SRC-1) has a crucial role in many different biological effects mediated by nuclear receptors. However, in spite of its ubiquitous expression, there are no data regarding its possible involvement in nuclear receptor transcriptional activity at the level of the peripheral nervous system. We investigated whether this coactivator might have a role in the control of glycoprotein Po gene expression. This myelin protein is a specific product of Schwann cells, with a fundamental role in the maintenance and functionality of peripheral myelin. Po is known to be stimulated by progesterone and by its 5alpha-reduced metabolite, dihydroprogesterone (DHP), through the corresponding steroid receptor. To determine whether the effect exerted by DHP on Po mRNA levels could be affected by and therefore associated with altered levels of SRC-1, a mouse Schwann cell line was stably transfected to over- or underexpress this coactivator. We found that SRC-1 overexpressing cells are more responsive to Po mRNA induction by DHP, whereas the effect of the steroid is completely lost in SRC-1-deficient cells. Interestingly, SRC-1 levels are also positively correlated with Po gene expression independently of DHP exposure. Finally, DHP treatment increases not only Po but also SRC-1 mRNA levels. Altogether, these data indicate for the first time that in rat Schwann cells, SRC-1 plays a role in the regulation of one of the most typical proteins of peripheral myelin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.